Abstracts Archive - Page 1570 of 2607 - ACR Meeting Abstracts

Abstract Number: 2741 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Factor (RF) Levels Remain Persistently Elevated 24 Weeks after Interferon (INF) Free Direct Antiviral Agents (DAA) Therapy in the Majority of RF+ HCV Infected Persons
Corinne Kowal¹, Carey Shive^2,3, Elizabeth Zebrowski^4,5, Lenche Kostadinova^1,6, Brianna Fuller^1,6, Elane Reyes², Kelsey Rife⁴, Amy Hirsch⁴, Anita Compan⁴, Shyam Kottilil⁷, Yngve Falck-Ytter^6,8, Leonard H. Calabrese⁹, Donald Anthony^4,6,10,11 and Maya Mattar^6,12, ¹Department of Medicine, Louis Stokes VA Medical Center, Cleveland, OH, ²Department of Medicine and Pathology, Case Western Reserve University, Cleveland, OH, ³VA Geriartic Research and Education Clinical Center (GRECC), Louis Stokes VA Medical Center, Cleveland, OH, ⁴Louis Stokes VA Medical Center, Cleveland, OH, ⁵Department of Medicine, Case Western Reserve University, Cleveland, OH, ⁶Case Western Reserve University, Cleveland, OH, ⁷IHV Clinical Research Unit, University of Maryland, Baltimore,, Baltimore, MD, ⁸Internal Medicine/ Division of gastroenterology, Louis Stokes VA Medical Center, Cleveland, OH, ⁹Rheumatic & Immunologic Disease and Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, ¹⁰Division of Medicine and Pathology, Divisions of Infectious and Rheumatic diseases, University Hospitals Cleveland Medical Center, Cleveland, OH, ¹¹VA Geriatric Research and Education Clinical Center (GRECC), Cleveland, OH, ¹²Internal Medicine/ Division of Rheumatology, University Hospitals Cleveland Medical Center, Cleveland, OH
Background/Purpose: Cryoglobulinemic vasculitis (CV) is an extrahepatic manifestation of chronic HCV infection. It varies in severity from mild to life threatening. Some but not all…
Abstract Number: 2742 • 2017 ACR/ARHP Annual Meeting
A Retrospective Study Comparing the Phenotype and Outcomes of Patients with Polyarteritis Nodosa between UK and Turkish Cohorts
Omer Karadag^1,2, Abdulsamet Erden², Yelda Bilginer², Seerapani Gopaluni¹, Alper Sari², Berkan Armagan², Ihsan Ertenli², Seza Ozen² and David Jayne³, ¹Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, ²Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ³Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Polyarteritis Nodosa (PAN) is a rare subgroup of the primary vasculitides. There are only two published cohorts describing demographic and clinical features of the disease.…
Abstract Number: 2743 • 2017 ACR/ARHP Annual Meeting
Requirement and Response Rates of Biologic Agents in Polyarteritis Nodosa (PAN)
Omer Karadag^1,2, Berkan Armagan², Abdulsamet Erden², Seerapani Gopaluni¹, Alper Sari², Sedat Kiraz² and David Jayne³, ¹Vasculitis and Lupus Clinic, Addenbrooke’s Hospital, University of Cambridge, Cambridge, United Kingdom, ²Hacettepe University Vasculitis Center (HUVAC), Ankara, Turkey, ³Vasculitis and Lupus Clinic, Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: Recent studies highlight the usefulness and necessity of biologic agents in the treatment of primary vasculitides. Evidence for the use of biologics in PAN…
Abstract Number: 2744 • 2017 ACR/ARHP Annual Meeting
Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment
Petros P Sfikakis¹, Aikaterini Arida¹, Stylianos Panopoulos², Kalliopi Fragkiadaki², George Pentazos³, Katerina Laskari³, Maria Tektonidou¹ and Nikos Markomichelakis², ¹First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, athens, Greece, ²First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, ³Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece
Background/Purpose: Anti-TNF treatment has been shown to be effective in inducing complete remission in many Behcet’s disease (BD) patients with eye, large vessel, intestine and…
Abstract Number: 2745 • 2017 ACR/ARHP Annual Meeting
Prevalence of Vasculitides As Extraintestinal Manifestation of Inflammatory Bowel Disease (IBD)
Sarah Ifteqar¹, Jason Springer² and Mehrdad Maz³, ¹Department of Medicine, Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ²Department of Internal Medicine, Division of Allergy, Clinical Immunology, & Rheumatology, Kansas University Medical Center, Kansas City, KS, ³Allergy, Clinical Immunology, and Rheumatology, Division of Allergy, Clinical Immunology and Rheumatology, Department of Internal Medicine, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: The extraintestinal manifestations of Inflammatory Bowel Disease (IBD) are identified in 6%-40% of patients. Systemic vasculitides may present as extraintestinal manifestations of IBD. The purpose…
Abstract Number: 2746 • 2017 ACR/ARHP Annual Meeting
Comparison between IgG and IgM Type Anti-Alpha-Enolase Antibody in Patients with Behcet’s Disease According to the Disease Severity
Shin Eui Kang¹, Sang Jin Lee^1,2, Hyun Jung Yoo^1,3, Jeong Yeon Kim¹, Ji Soo Park¹, Sehui Shon⁴, Eun Young Lee³, Eun Bong Lee³ and Yeong Wook Song^1,3, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ⁴Department of Molecular Medicine and Biopharmaceutical Sciences, Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, Korea, Republic of (South)
Background/Purpose: Behcet’s disease (BD) is a chronic inflammatory disease of unknown etiology, characterized by recurrent oral and genital ulcers, skin lesions, uveitis, and arthritis. It…
Abstract Number: 2747 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide
Mert Gurcan¹, Sinem Nihal Esatoglu¹, Vedat Hamuryudan¹, Caner Saygin², Didem Saygin³, Serdal Ugurlu⁴, Emire Seyahi¹, Melike Melikoglu¹, Izzet Fresko¹, Sebahattin Yurdakul¹, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Cleveland, OH, ³Internal Medicine, Department of Internal Medicine, Cleveland Clinic, Cleveland, Cleveland, OH, ⁴Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Cyclophosphamide (CYC) remains an important treatment option for Behçet’s syndrome (BS) pts with life threatening conditions such as arterial aneurysms. However, several adverse events…
Abstract Number: 2748 • 2017 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study
Sinem Nihal Esatoglu¹, Fatma Nihan Akkoc¹, Yesim Ozguler¹, Fatma Ozbakir², Okan Kadir Nohut², Dilsen Cevirgen³, Vedat Hamuryudan¹, Ibrahim Hatemi⁴, Aykut Ferhat Celik⁵, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Central Research Laboratory, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of and Rheumatology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Immunogenicity of anti-TNFs has been recognized as an important problem that may cause loss of response and adverse events such as infusion reactions. We…
Abstract Number: 2749 • 2017 ACR/ARHP Annual Meeting
Four-Distinct Phenotypes of Patients with Necrotizing Arteritis of Medium and Small Arteries
Tsuyoshi Shirai¹, Hiroshi Fujii¹, Yoko Fujita², Yuko Shirota¹, Tomonori Ishii¹ and Hideo Harigae¹, ¹Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, ²Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan
Background/Purpose: Polyarteritis nodosa (PAN) is a necrotizing arteritis of medium and small arteries. PAN is divided into systemic and cutaneous PAN (cPAN). cPAN can be…
Abstract Number: 2750 • 2017 ACR/ARHP Annual Meeting
A Serum Metabolomic Analysis in Behcet’s Disease: A Preliminary Study
Wenjie Zheng¹, Xiuhua Wu^1,2, Maryam Goudarzi³, Hua Chen¹, JinJing Liu¹, Jing Shi¹, Chaoran Li¹, Mengyu Zhou⁴, Wen Zhang¹, Xuan Zhang¹ and Henghong Li³, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Rheumatology, General Hospital of Tianjin Medical University, Tianjing, China, ³Georgetown University Medical Center, Georgetown University, Washington, DC, WA, ⁴Peking Union Medical College Hospital, Beijing, China
Background/Purpose: The diagnosis of Behçet's disease (BD) is mainly based on clinical manifestations and remains a challenge in clinical practice, due to the fact that…
Abstract Number: 2751 • 2017 ACR/ARHP Annual Meeting
Tocilizumab in the Treatment of Severe and/or Refractory Behcet’s Disease：a Single-Centre Experience in China
Wenjie Zheng¹, Yanxia Ding^1,2, Di Wu¹, Jiaxin Zhou¹, JinJing Liu¹, Dong Yan¹, Mengyu Zhou³, Yan Zhao¹ and Fengchun Zhang³, ¹Rheumatology, Peking Union Medical College Hospital, Beijing, China, ²Rheumatology, The First Affiliated Hospital of Zhengzhou, Zhengzhou, China, ³Peking Union Medical College Hospital, Beijing, China
Background/Purpose: To report the efficacy and safety of tocilizumab(TCZ) for the treatment of severe and/or refractory Behçet's disease(BD). Methods: We retrospectively analyzed the efficacy and…
Abstract Number: 2752 • 2017 ACR/ARHP Annual Meeting
Risk of Hospitalizations for Venous Thromboembolism Among Patients with Selected Systemic Vasculitides: A Nationwide Analysis
Yiming Luo¹, Jiehui Xu², Yumeng Wen¹, Alvaro Ramos-Rodriguez¹, Changchuan Jiang¹, Shuyang Fang¹, Mustafa Kagalwalla¹ and Neha Ohri³, ¹Department of Medicine, Mount Sinai St Luke's and Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ²Department of Biostatistics, Mailman School of Public Health, Columbia University Medical Center, New York, NY, ³Division of Rheumatology, Department of Medicine, Mount Sinai St Luke's and Mount Sinai West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Venous thromboembolism (VTE) contributes significantly to in-hospital morbidity and mortality. Previous studies have suggested that certain vasculitides, including granulomatosis with polyangiitis (GPA) and giant…
Abstract Number: 2753 • 2017 ACR/ARHP Annual Meeting
Brain Functional Connectivity Features of Pain Centralisation Relate to Degree of ‘Fibromyalgianess’ in Rheumatoid Arthritis
Neil Basu¹, Chelsea Cummiford², Eric Ichesco², Tony Larkin², Richard E. Harris², Alison Murray³, Gordon Waiter⁴ and Daniel J. Clauw⁵, ¹Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, United Kingdom, ²Chronic Pain and Fatigue Research Center, University of Michigan, Ann Arbor, MI, ³Aberdeen Brain Imaging Center, University of Aberdeen, Aberdeen, United Kingdom, ⁴Aberdeen Brain Imaging Centre, University of Aberdeen, Aberdeen, United Kingdom, ⁵Anesthesiology, University of Michigan, Ann Arbor, MI
Background/Purpose: Many rheumatoid arthritis (RA) patients continue to report pain despite excellent control of inflammation with immunotherapy regimes. Variable degrees of co-existing fibromyalgia (FM) may…
Abstract Number: 2754 • 2017 ACR/ARHP Annual Meeting
Comparison of Individually Tailored Vs Systematic Rituximab Regimens to Maintain ANCA-Associated Vasculitis Remissions: Results of a Prospective, Randomized–Controlled, Phase 3 Trial
Pierre Charles¹, Benjamin Terrier², Elodie Perrodeau³, Pascal Cohen², Stanislas Faguer⁴, Antoine Huart⁵, Mohamed Hamidou⁶, Christian Agard⁷, Bernard Bonnotte⁸, Maxime Samson⁸, Alexandre Karras⁹, Noémie Jourde-Chiche¹⁰, François Lifermann¹¹, Pierre Gobert¹², Catherine Hanrotel-Saliou¹³, Pascal Godmer¹⁴, Nicolas Martin Silva¹⁵, Grégory Pugnet¹⁶, Marie Matignon¹⁷, Olivier Aumaître¹⁸, Estibaliz Lazaro¹⁹, Xavier Puéchal²⁰, Philippe Ravaud²¹, Luc Mouthon²² and Loïc Guillevin²⁰, ¹Service de Médecine Interne, Hôpital Cochin, Paris, France, ²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ⁴2Service de Néphrologie et Immunologie Clinique, Centre Hospitalier Universitaire (CHU) de Toulouse, Toulouse, France, ⁵CHU, Toulouse, France, ⁶Internal Medicine Department, Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁷Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁸Department of Internal Medicine and Clinical Immunology, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁹Nephrology, HEGP, Paris, France, ¹⁰Vascular Research Center of Marseille, Aix-Marseille Univ., Vascular Research Center of Marseille, Marseille, France, ¹¹Dax, Dax, France, ¹²Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹³Brest, Brest, France, ¹⁴Medecine Interne, CH Vannes, Vannes, France, ¹⁵Department of Internal Medicine, Caen University Hospital, Caen, France, ¹⁶Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ¹⁷Service de Néphrologie, Hôpital Henri-Mondor, Créteil, Créteil, France, ¹⁸CHU Pitié-Salpêtrière - Department of Internal Medicine 2. Referal center for SLE/APS, Paris, France, ¹⁹service de médecine interne et maladies infectieuses, CHU de Bordeaux, Pessac, France, ²⁰National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²¹Hôpital Hôtel Dieu, Paris, France, ²²Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: Once ANCA-associated vasculitis (AAV) remission was obtained, rituximab (RTX) superiority to azathioprine (AZA) to maintain remission was shown.1 In that study, at month 28,…
Abstract Number: 2755 • 2017 ACR/ARHP Annual Meeting
Comparative Risk of Biologic Therapies in Patients with Rheumatoid Arthritis Undergoing Elective Arthroplasty
Michael D. George¹, Joshua Baker², Kevin Winthrop³, E Alemao⁴, Lang Chen⁵, SE Connolly⁴, TA Simon⁴, Qufei Wu⁶, Fenglong Xie⁷, Shuo Yang⁷ and Jeffrey R. Curtis⁸, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Oregon Health Sciences University, Portland, OR, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Biologic DMARDs have varying mechanisms of action and may be associated with different infection risks. The perioperative time period is a particularly high-risk time…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].